Represented a provider of enterprise software solutions in the Delaware Chancery Court and Delaware Supreme Court in the trial and appeal of the first case to challenge the validity of a 4.99% shareholder rights plan (or net operating loss ?poison pill?), arising from the triggering of the pill and the subsequent dilution of the investor?s holdings.